CYIENT

Microsoft Solutions Partner

Data & AI
Azure

3X FASTER PROCESSING. HIGHER ACCURACY. 40% MORE BUSINESS VALUE. POWERED BY OUR GLOBAL REGULATORY MONITORING AND INTELLIGENCE PLATFORM FOR MDR COMPLIANCE.

About Cyient

Partnering with over 300 customers, including 40% of the top 100 global innovators, we solve today's problems to create a digital, autonomous, and sustainable tomorrow. We unite deep MedTech domain knowledge, comprehensive silicon-to-software engineering capabilities, and cutting-edge AI platforms to transform visionary concepts into market-leading solutions with sustainable impact. Our integrated approach enables organizations to drastically reduce time-to-market, ensure regulatory compliance, maintain first mover advantage & optimize total lifecycle investments from inception.

What We Offer

The solution transforms workflows to address the EU MDD to MDR transition by specific AI Copilots or Intelligent Agents that accelerate execution, ensure compliance, improve accuracy, and deliver interactive experiences. Together, Cyient and Microsoft platforms offer industry-first, engineering-led business process solution bring in 3X faster document processing time, 40 % reduced operational cost combined with significant accuracy improvement than the conventional process. Some of the salient feature of the solution.

- Agentic AI-driven framework
- MCP (Model Context Protocol)
- Pre-built connectors with knowledge bases
- Cloud-native, microservices architecture ensuring security
- Continuous compliance to industry needs

The MDD to MDR transition is a defining moment for medical device companies. For the Chief of Quality, Safety, and Patient Officer, it presents a rare challenge and opportunities to lead with purpose — aligning regulatory rigor with Technology-centric innovation and operational excellence.

Industry Challenge

Legacy medical devices must meet the new, modernized and more stringent requirements of the EU MDR to continue being placed on the market in the future.

MDD to MDR Transition timelines:

Class III custom-made implantable devices:
until May 26, 2026

Other Class III and Class IIb implantables:
until December 31, 2027

Class IIa and Class I devices:
until December 31, 2028